Please login to the form below

Not currently logged in
Email:
Password:

Sanofi launches diabetes drug Lyxumia in the UK

Says drug could make multimillion pound savings for the NHS

Sanofi's Lyxumia (lixisenatide) 

Sanofi has launched its new diabetes drug Lyxumia in the UK and says the drug could bring big cost savings for the NHS.

A GLP-1 agonist, Lyxumia (lixisenatide) won European approval in February for use as a single daily injection alongside an oral glucose-lowering medicinal products and/or basal insulin in patients with inadequate glycaemic control.

Lyxumia's pricing will see it undercut its rival GLP-1 agonists Byetta (exenatide), now owned by Bristol-Myers Squibb, and Novo Nordisk's Victoza (liraglutide) in the UK.

Lyxumia will cost £54.14 for 28 days of treatment, compared to £68.24 for 30 days of treatment with Byetta and £78.48 for 30 days of treatment with Victoza. 

Sanofi estimated that if all new GLP-1 patients were started on Lyxumia from the second quarter of 2013, the NHS could save £70.8m by the end of 2017.

Caroline Horwood, diabetes division director, said: "Sanofi recognises the cost pressures facing the NHS in today's financial climate and our diabetes portfolio is focused on trying to help people manage the complex challenges of diabetes by delivering innovative medicines that meet patient needs.

"We are delighted to be offering the NHS another high quality diabetes medicine that's easy for patients to use. The price is one that represents real value to both the NHS and Sanofi."

The drug's approval was based on data from the GetGoal clinical programme, which demonstrated that Lyxumia was able to reduce blood sugar levels and has a beneficial effect on body weight in patients with type 2 diabetes, with only a limited risk of hypoglycaemia.

The economic impact of severe hypoglycaemia in the UK is estimated at £30.4m and for moderate hypoglycaemia £41.8m, both of which Sanofi hopes its drug will help with. 

Sanofi has been putting a lot of resources recently into diabetes, where its key therapy in Lantus (insulin glargine), which Lyxumia is able to complement as an add-on therapy.

2nd May 2013

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...

Infographics